OSIRIS THERAPEUTICS, INC.

Form 3

February 12, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

Expires:

3235-0104

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response... Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

Czworka Frank D Jr

INC., Â 7015 ALBERT EINSTEIN DRIVE

(Last)

(First)

C/O OSIRIS THERAPEUTICS,

(Street)

(Middle)

Statement

(Month/Day/Year)

02/06/2014

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

OSIRIS THERAPEUTICS, INC. [OSIR]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

(Check all applicable)

Director _X__ Officer

10% Owner Other

(give title below) (specify below) Vice President

6. Individual or Joint/Group Filing(Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One

Reporting Person

COLUMBIA. MDÂ 21046

(City) (State) (Zip)

1. Title of Security (Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities

Beneficially Owned (Instr. 4)

3. Ownership 4. Nature of Indirect Beneficial Ownership

(Instr. 5) Form:

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(Instr. 4)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4 Conversion or Exercise

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership

Date Expiration

Exercisable Date Title Amount or Number of Price of Derivative Security

(Instr. 5)

Security: Direct (D)

Edgar Filing: OSIRIS THERAPEUTICS, INC. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Incentive Stock Option (right to buy)	08/22/2012	08/22/2021	Common Stock	17,500	\$ 5.08	D	Â
Incentive Stock Option (right to buy)	03/23/2013	03/23/2022	Common Stock	11,250	\$ 5.08	D	Â
Incentive Stock Option (right to buy)	02/12/2014	02/12/2023	Common Stock	20,000	\$ 7.73	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
· F · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Other		
Czworka Frank D Jr C/O OSIRIS THERAPEUTICS, INC. 7015 ALBERT EINSTEIN DRIVE COLUMBIA, MD 21046	Â	Â	Vice President	Â		

Signatures

Frank D.
Czworka, Jr.

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2